Literature DB >> 2158690

Expression of hepatitis B virus core and precore antigens in insect cells and characterization of a core-associated kinase activity.

R E Lanford1, L Notvall.   

Abstract

The hepatitis B virus core open reading frame with and without the precore domain was expressed in insect cells using a baculovirus expression system. Precore antigen was not properly processed in insect cells and was present in highly insoluble cytoplasmic aggregates. Core antigen without the precore domain formed core particles with a diameter of 28 nm that were secreted into the medium. Both core and precore antigens were phosphorylated in insect cells. The immune response in mice to both antigens yielded antibodies with a high degree of preferential reactivity for the homologous immunizing polypeptide. A kinase activity that phosphorylated core antigen was associated with highly purified core particles. The kinase activity resembled that previously demonstrated for core particles purified from the cytoplasm of infected hepatocytes and detergent-treated Dane particles. Partial resistance of the phosphate-label to phosphatase treatment suggested that some of the phosphorylated sites are in the interior of the particle. The presence of kinase activity in recombinant core particles demonstrated that this activity is not derived from another hepatitis B virus-encoded polypeptide, and the lack of a kinase consensus sequence in the core open reading frame suggests that the kinase is of cellular origin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2158690     DOI: 10.1016/0042-6822(90)90247-o

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  31 in total

1.  Core protein phosphorylation modulates pregenomic RNA encapsidation to different extents in human and duck hepatitis B viruses.

Authors:  E V Gazina; J E Fielding; B Lin; D A Anderson
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  Interaction between hepatitis B virus core protein and reverse transcriptase.

Authors:  L Lott; B Beames; L Notvall; R E Lanford
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Effects of mutations within and adjacent to the terminal repeats of hepatitis B virus pregenomic RNA on viral DNA synthesis.

Authors:  S Perri; D Ganem
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Characterization of hepatitis B virus capsid particle assembly in Xenopus oocytes.

Authors:  S Zhou; S Q Yang; D N Standring
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

5.  Phosphorylation in the carboxyl-terminal domain of the capsid protein of hepatitis B virus: evaluation with a monoclonal antibody.

Authors:  A Machida; H Ohnuma; F Tsuda; A Yoshikawa; Y Hoshi; T Tanaka; S Kishimoto; Y Akahane; Y Miyakawa; M Mayumi
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

Review 6.  The diverse functions of the hepatitis B core/capsid protein (HBc) in the viral life cycle: Implications for the development of HBc-targeting antivirals.

Authors:  Ahmed Diab; Adrien Foca; Fabien Zoulim; David Durantel; Ourania Andrisani
Journal:  Antiviral Res       Date:  2017-11-26       Impact factor: 5.970

7.  A protease-sensitive hinge linking the two domains of the hepatitis B virus core protein is exposed on the viral capsid surface.

Authors:  M Seifer; D N Standring
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

8.  Phosphorylation of the core protein of hepatitis B virus by a 46-kilodalton serine kinase.

Authors:  J H Kau; L P Ting
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

9.  Effect of core protein phosphorylation by protein kinase C on encapsidation of RNA within core particles of hepatitis B virus.

Authors:  M Kann; W H Gerlich
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

10.  Insertions within the hepatitis B virus capsid protein influence capsid formation and RNA encapsidation.

Authors:  B Beames; R E Lanford
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.